-
Health Plus Receives Strategic Investment from Meinian Onehealth to Drive Healthcare Innovation
•
Beijing-based Health Plus, a third-party digital managed healthcare service platform, has received strategic investment from Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044), also known as Health-100. The partnership will see both companies collaborate on commercial insurance product innovation, medical network construction, and healthcare service integration. Collaboration DetailsThe two firms…
-
Prismlab China Raises USD 29.1M in Series C for 3D Printing Expansion
•
Shanghai-based 3D printing solution provider Prismlab China Ltd has raised RMB 200 million (USD 29.1 million) in a Series C financing round led by Qiming Venture Partners, with participation from BASF Venture Capital and Jolmo Investment. The proceeds will fund business expansion, product upgrades, warehouse growth, talent recruitment, and R&D.…
-
Junshi Biosciences’ TAB009/JS009 and JS110 Advance in Cancer Trials
•
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration (NMPA) to conduct a clinical trial for its injectable monoclonal antibody TAB009/JS009, targeting CD112R, as a monotherapy for advanced solid tumors. The company also plans to initiate a US trial for its XPO1 inhibitor JS110…
-
Illumina Opens First China Manufacturing Base for Gene Sequencers
•
US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking a strategic expansion in the world’s second-largest biotech market. The Shanghai plant, with a Phase 1 investment of RMB 50 million (USD 7.2 million), aims to localize production of high-end gene sequencers and consumables over…
-
Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study
•
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration (NMPA) to conduct a clinical trial for its injectable monoclonal antibody TAB009/JS009, targeting CD112R, in advanced solid tumors. The company also plans to initiate a US trial for its XPO1 inhibitor JS110 after gaining FDA…
-
Illumina Opens First China Manufacturing Base for Gene Sequencers
•
US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking a strategic expansion in the world’s second-largest biotech market. The Shanghai plant, with a Phase 1 investment of RMB 50 million (USD 7.2 million), aims to localize production of high-end gene sequencers and consumables over…
-
Novartis to Spin Off Sandoz, Focus on Innovative Drugs
•
Swiss drugmaker Novartis announced plans to spin off its generic and biosimilar unit, Sandoz, to sharpen its focus on innovative therapies. The move aims to maximize shareholder value by listing Sandoz on the SIX Swiss Exchange, positioning it as Europe’s largest generic company and a global biosimilars leader. Spin-Off DetailsThe…
-
Clover Biopharmaceuticals’ SCB-2019 Vaccine Proves Effective in Teenagers
•
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial of its SCB-2019 (CpG 1018/Alum) COVID-19 vaccine in adolescents aged 12 to 17. The study demonstrated superior immune response in teenagers compared to young adults, reinforcing the vaccine’s efficacy. Study Highlights Global Regulatory StrategyClover Bio…
